Intellia Therapeutics, Inc. financial data

Symbol
NTLA on Nasdaq
Location
Cambridge, MA
Fiscal year end
31 December
Latest financial report
10-K - Q4 2025 - 26 Feb 2026

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 532% % -25%
Debt-to-equity 25% % -0.18%
Return On Equity -57% % -4.8%
Return On Assets -45% % -4.8%
Operating Margin -652% % 29%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 118,133,546 shares 14%
Common Stock, Shares, Outstanding 116,317,060 shares 14%
Entity Public Float $869,490,759 USD -55%
Common Stock, Value, Issued $12,000 USD 20%
Weighted Average Number of Shares Outstanding, Basic 108,376,000 shares 9.6%
Weighted Average Number of Shares Outstanding, Diluted 108,376,000 shares 9.6%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax $67,671,000 USD 17%
Research and Development Expense $388,861,000 USD -17%
General and Administrative Expense $119,800,000 USD -4.8%
Costs and Expenses $508,661,000 USD -14%
Operating Income (Loss) $440,990,000 USD 17%
Net Income (Loss) Attributable to Parent $412,694,000 USD 20%
Earnings Per Share, Basic -3.81 USD/shares 27%
Earnings Per Share, Diluted -3.81 USD/shares 27%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $155,464,000 USD -18%
Marketable Securities, Current $294,420,000 USD -29%
Accounts Receivable, after Allowance for Credit Loss, Current $9,468,000 USD 11%
Assets, Current $527,711,000 USD -18%
Property, Plant and Equipment, Net $17,671,000 USD -35%
Operating Lease, Right-of-Use Asset $105,955,000 USD -52%
Assets $842,127,000 USD -29%
Accounts Payable, Current $20,252,000 USD 39%
Employee-related Liabilities, Current $23,072,000 USD -4.2%
Accrued Liabilities, Current $49,862,000 USD -9.9%
Contract with Customer, Liability, Current $7,290,000 USD -65%
Liabilities, Current $103,884,000 USD -6.3%
Contract with Customer, Liability, Noncurrent $0 USD -100%
Operating Lease, Liability, Noncurrent $66,849,000 USD -65%
Liabilities $170,733,000 USD -46%
Accumulated Other Comprehensive Income (Loss), Net of Tax $1,032,000 USD 71%
Retained Earnings (Accumulated Deficit) $2,590,094,000 USD -19%
Stockholders' Equity Attributable to Parent $671,394,000 USD -23%
Liabilities and Equity $842,127,000 USD -29%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $148,930,000 USD -23%
Net Cash Provided by (Used in) Financing Activities $0 USD -100%
Net Cash Provided by (Used in) Investing Activities $94,328,000 USD 1499%
Common Stock, Shares Authorized 240,000,000 shares 0%
Common Stock, Shares, Issued 116,317,060 shares 14%
Common Stock, Par or Stated Value Per Share 0.0001 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $54,602,000 USD 0.3%
Deferred Tax Assets, Valuation Allowance $914,641,000 USD 17%
Deferred Tax Assets, Gross $944,561,000 USD 12%
Operating Lease, Liability $93,329,000 USD -56%
Payments to Acquire Property, Plant, and Equipment $735,000 USD -71%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $412,267,000 USD 20%
Lessee, Operating Lease, Liability, to be Paid $111,239,000 USD -62%
Property, Plant and Equipment, Gross $76,277,000 USD -1%
Operating Lease, Liability, Current $26,480,000 USD 31%
Lessee, Operating Lease, Liability, to be Paid, Year Two $24,125,000 USD -36%
Lessee, Operating Lease, Liability, to be Paid, Year One $32,219,000 USD -8.2%
Operating Lease, Weighted Average Discount Rate, Percent 0.0754 pure 1.2%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $17,910,000 USD -79%
Lessee, Operating Lease, Liability, to be Paid, Year Three $15,637,000 USD -51%
Deferred Tax Assets, Operating Loss Carryforwards $457,009,000 USD 54%
Unrecognized Tax Benefits $0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four $12,666,000 USD -53%
Depreciation, Depletion and Amortization $9,767,000 USD -5%
Deferred Tax Assets, Net of Valuation Allowance $29,920,000 USD -51%
Share-based Payment Arrangement, Expense $80,219,000 USD -48%